Dual RAF-MEK Inhibitor Assessed

    Cancer Discovery
    |November 14, 2020
    PubMed

    Insights

    VS-6766, a novel dual RAF-MEK inhibitor, demonstrated safety and efficacy in early trials for solid tumors and multiple myeloma with RAS-RAF mutations.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Pharmacology

    Background:

    • RAF and MEK proteins are key components of the RAS-RAF-MEK-ERK signaling pathway.
    • Mutations in RAS and RAF genes are common drivers in various solid tumors and multiple myeloma.
    • Targeting this pathway offers a therapeutic strategy for cancers with these mutations.